Damaso Oliva, MD
Psychiatry · San Antonio, TXNPI 1659304350
Payments from drug & device makers
Across 2,262 payments — averaging $116.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$101K
- Neurocrine Biosciences, Inc.$72K
- Avanir Pharmaceuticals, Inc.$61K
- Teva Pharmaceuticals USA, Inc.$5K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$4K
- Johnson & Johnson$3K
- plus $17K from 19 others
What the payments were for
- Consulting fees$32,07219%
- Speaking & faculty fees$91,69754%
- Travel & lodging$7,8215%
- Food & beverage$38,37523%
- Education$5300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 309 | $100,869 |
| Neurocrine Biosciences, Inc. | 217 | $71,601 |
| Avanir Pharmaceuticals, Inc. | 20 | $61,345 |
| Teva Pharmaceuticals USA, Inc. | 334 | $4,925 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 212 | $4,323 |
| Johnson & Johnson | 192 | $3,146 |
| E.r. Squibb & Sons, L.L.C. | 38 | $3,079 |
| Otsuka America Pharmaceutical, Inc. | 210 | $2,956 |
| Sunovion Pharmaceuticals Inc. | 157 | $2,694 |
| AbbVie(2 entities) | 162 | $2,153 |
| Lundbeck LLC | 131 | $1,601 |
| Merck | 70 | $846 |
| Almatica Pharma LLC | 45 | $776 |
| Axsome Therapeutics, Inc. | 31 | $713 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $601 |
| Vanda Pharmaceuticals Inc. | 25 | $448 |
| Eisai Inc. | 15 | $426 |
| Alfasigma USA, Inc. | 15 | $328 |
| Idorsia Pharmaceuticals US Inc | 15 | $226 |
| Noven Therapeutics, LLC | 12 | $146 |
| Corium, LLC | 5 | $110 |
| Biogen | 5 | $81 |
| Jazz Pharmaceuticals Inc. | 3 | $62 |
| Noven Pharmaceuticals, Inc. | 2 | $44 |
| Luye Pharma (USA) Ltd. | 2 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$257,298
- INGREZZA$67,630
- ARISTADA$2,408
- ARISTADA INITIO$488
- CAPLYTA$374
- COBENFY$250
- REXULTI$248
- LATUDA$240
- VRAYLAR$230
- INVEGA SUSTENNA$150
- INVEGA TRINZA$150
- ABILIFY ASIMTUFII$139
- AUSTEDO$132
- Auvelity$125
- Fanapt$122
- Dayvigo$113
How this compares
$263,538 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 135 | $1,094,944 |
| AuvelityDextromethorphan Hbr/Bupropion | 685 | $650,492 |
| LybalviOlanzapine/Samidorphan Malate | 330 | $520,757 |
| AristadaAripiprazole Lauroxil | 165 | $513,117 |
| RexultiBrexpiprazole | 288 | $437,493 |
| Invega SustennaPaliperidone Palmitate | 134 | $389,489 |
| Invega TrinzaPaliperidone Palmitate | 23 | $197,075 |
| CaplytaLumateperone Tosylate | 112 | $181,518 |
| TrintellixVortioxetine Hydrobromide | 197 | $106,574 |
| VraylarCariprazine Hcl | 62 | $88,344 |
| BelsomraSuvorexant | 117 | $52,216 |
| Lurasidone Hcl | 97 | $22,053 |
| QuviviqDaridorexant Hcl | 37 | $18,241 |
| Rivastigmine | 94 | $14,426 |
| NamzaricMemantine Hcl/Donepezil Hcl | 20 | $12,991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $71,601 | $1,094,944135 claims |
| Alkermes, Inc.Lybalvi, Aristada | $100,869 | $1,033,873495 claims |
| Axsome Therapeutics, Inc.Auvelity | $713 | $650,492685 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $3,146 | $586,564157 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,956 | $437,493288 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $4,323 | $181,518112 claims |
| AbbVieVraylar, Namzaric, Fetzima | $2,153 | $110,280100 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $601 | $106,574197 claims |
| MerckBelsomra | $846 | $52,216117 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $226 | $18,24137 claims |
| Almatica Pharma LLCSertraline Hcl, Loreev Xr | $776 | $10,221262 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in San Antonio
- Thomas WeissSan Antonio$1.1M
- Jason MillerSan Antonio$869K
- Nathan JohnstonSan Antonio$435K
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.